Global Short Bowel Syndrome (SBS) Industry

Global Short Bowel Syndrome (SBS) Industry

  • April 2021 •
  • 132 pages •
  • Report ID: 6043394 •
  • Format: PDF
Abstract:
- Global Short Bowel Syndrome (SBS) Market to Reach $3.7 Billion by 2027
- Amid the COVID-19 crisis, the global market for Short Bowel Syndrome (SBS) estimated at US$665.4 Million in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 27.6% over the analysis period 2020-2027. GLP-2, one of the segments analyzed in the report, is projected to record a 29% CAGR and reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Growth Hormone segment is readjusted to a revised 26.4% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $199.7 Million, While China is Forecast to Grow at 26.8% CAGR
- The Short Bowel Syndrome (SBS) market in the U.S. is estimated at US$199.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$627.8 Million by the year 2027 trailing a CAGR of 26.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 25% and 23.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 19.2% CAGR.
- Glutamine Segment to Record 23.6% CAGR
- In the global Glutamine segment, USA, Canada, Japan, China and Europe will drive the 23.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$19.7 Million in the year 2020 will reach a projected size of US$86.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433 Million by the year 2027.

- Select Competitors (Total 42 Featured) -
  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • Merck KgaA
  • Naia Pharmaceuticals Inc.
  • Nutrien Ltd.
  • OxThera AB
  • Shire PLC
  • Zealand Pharma A/S